ARTICLE | Product Development
Not poly pills
July 25, 2005 7:00 AM UTC
Having reloaded last week with a $36 million series B financing, Ilypsa Inc. will look to get clinical proof-of-concept for its ILY-101 polymeric phosphate binder, which the company thinks can improve upon marketed drugs for end-stage renal disease.
The company figures the market belongs to polymer-based solutions, specifically Genzyme Corp.'s Renagel sevelamer, which posted second quarter sales of $100.8 million, up 15% from the same period last year. ...